Long-term efficacy and safety of prophylactic treatment with recombinant factor IX FC fusion protein (rFIXFc) in subjects with severe or moderate haemophilia B: final longitudinal analysis of B-LONG/kids B-LONG and B-YOND

被引：0
|
作者：
Shapiro, A. D. [1 ]
Kulkarni, R. [2 ]
Ragni, M. V. [3 ]
Mahlangu, J. [4 ,5 ]
Oldenburg, J. [6 ]
Nolan, B. [7 ]
Ozelo, M. C. [8 ]
Willemze, A. [9 ]
Feng, J. [10 ]
Barnowski, C. [10 ]
Barnes, C. [11 ]
机构：
[1] Indiana Hemophilia & Thrombosis Ctr, Indianapolis, IN USA
[2] Michigan State Univ, E Lansing, MI 48824 USA
[3] Univ Pittsburgh, Hemophilia Ctr Western Penn, Pittsburgh, PA USA
[4] Univ Witwatersrand, Haemophilia Comprehens Care Ctr, Fac Hlth Sci, Johannesburg, South Africa
[5] NHLS, Johannesburg, South Africa
[6] Univ Clin Bonn, Inst Expt Haematol & Transfus Med, Bonn, Germany
[7] Our Ladys Childrens Hosp, Dublin, Ireland
[8] Univ Estadual Campinas, Hemoctr UNICAMP, Sao Paulo, Brazil
[9] Sobi, Stockholm, Sweden
[10] Bioverativ, Waltham, MA USA
[11] Royal Childrens Hosp, Melbourne, Vic, Australia
来源：
HAEMOPHILIA | 2019年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P009
引用
收藏
页码：39 / 40
页数：2
相关论文
共 50 条
  • [41] Clinical evaluation of a novel, long-lasting recombinant Fc fusion replacement factor (rFIXFc) in patients with severe haemophilia B
    Shapiro, A.
    Pasi, J.
    Gust, S.
    Defeofraulini, T.
    Thomas, G.
    Li, L.
    Dabora, S.
    Krassova, S.
    Luk, A.
    Pierce, G.
    HAEMOPHILIA, 2012, 18 : 40 - 40
  • [42] rFIXFc prophylaxis improves pain and levels of physical activity in haemophilia B: Post hoc analysis of B-LONG using haemophilia-specific quality of life questionnaires
    Astermark, Jan
    Hermans, Cedric
    Ezzalfani, Monia
    Aballea, Samuel
    Santagostino, Elena
    Hakimi, Zalmai
    Nazir, Jameel
    HAEMOPHILIA, 2022, 28 (01) : 18 - 26
  • [43] ANALYSIS OF ANNUALIZED BLEEDING RATES AND BASELINE CHARACTERISTICS IN SUBJECTS WITH A 14-DAY OR LONGER DOSING INTERVAL IN THE PHASE 3 B-LONG STUDY OF RECOMBINANT FACTOR IX FC FUSION PROTEIN
    Shapiro, Amy D.
    Kulkarni, Roshni
    Ozelo, Margareth
    Windyga, Jerzy
    Pasi, K. John
    Perry, David J.
    Desai, Chintu
    Mei, Baisong
    AMERICAN JOURNAL OF HEMATOLOGY, 2016, 91 (09) : E406 - E406
  • [44] EFFICACY OF RFIXFC VS RIX-FP FOR THE TREATMENT OF PATIENTS WITH HAEMOPHILIA B: MATCHING-ADJUSTED INDIRECT COMPARISON OF B-LONG AND PROLONG-9FP TRIALS
    Astermark, J.
    Wojciechowski, P.
    Aballea, S.
    Hakimi, Z.
    Nazir, J.
    Klamroth, R.
    HAEMOPHILIA, 2021, 27 : 68 - 68
  • [45] B-YOND Final Results Confirm Established Safety, Sustained Efficacy, and Extended Dosing Interval for Up to 4 Years of Treatment With rFIXFc in Previously Treated Subjects With Severe Hemophilia B
    Ragni, Margaret
    Kulkarni, Roshni
    Pasi, K. John
    Fischer, Kathelijn
    Mahlangu, Johnny
    Shapiro, Amy
    Nolan, Beatrice
    Oldenburg, Johannes
    Matsushita, Tadashi
    Willemze, Annemieke
    Yuan, Huixing
    Rudin, Dan
    BLOOD, 2018, 132
  • [46] Efficacy and safety of long-acting recombinant fusion protein linking factor IX with albumin in haemophilia B patients undergoing surgery
    Negrier, C.
    Karim, F. Abdul
    Lepatan, L. M.
    Lienhart, A.
    Lopez-Fernandez, M. F.
    Mahlangu, J.
    Pabinger, I.
    Li, Y.
    Wolko, D.
    Voigt, C.
    Jacobs, I.
    Santagostino, E.
    HAEMOPHILIA, 2016, 22 (04) : E259 - E266
  • [47] Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B
    Nathwani, A. C.
    Reiss, U. M.
    Tuddenham, E. G. D.
    Rosales, C.
    Chowdary, P.
    McIntosh, J.
    Della Peruta, M.
    Lheriteau, E.
    Patel, N.
    Raj, D.
    Riddell, A.
    Pie, J.
    Rangarajan, S.
    Bevan, D.
    Recht, M.
    Shen, Y. -M.
    Halka, K. G.
    Basner-Tschakarjan, E.
    Mingozzi, F.
    High, K. A.
    Allay, J.
    Kay, M. A.
    Ng, C. Y. C.
    Zhou, J.
    Cancio, M.
    Morton, C. L.
    Gray, J. T.
    Srivastava, D.
    Nienhuis, A. W.
    Davidoff, A. M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (21): : 1994 - 2004
  • [48] Long-term safety and efficacy of recombinant factor ix fusion protein (rIX-FP) in patients with haemophilia B: Interim results from an ongoing phase 3b extension study
    Santagostino, E.
    Pabinger, I.
    Brainsky, A.
    Li, Y.
    Seifert, W.
    HAEMOPHILIA, 2019, 25 : 80 - 81
  • [49] Post hoc longitudinal assessment of the efficacy and safety of recombinant factor IX Fc fusion protein in hemophilia B
    Shapiro, Amy D.
    Kulkarni, Roshni
    Ragni, Margaret V.
    Chambost, Herve
    Mahlangu, Johnny
    Oldenburg, Johannes
    Nolan, Beatrice
    Ozelo, Margareth C.
    Foster, Meredith C.
    Willemze, Annemieke
    Barnowski, Christopher
    Jain, Nisha
    Winding, Bent
    Dumont, Jennifer
    Lethagen, Stefan
    Barnes, Chris
    Pasi, K. John
    BLOOD ADVANCES, 2023, 7 (13) : 3049 - 3057
  • [50] Safety, Efficacy, and Pharmacokinetics of Recombinant Factor VIII FC Fusion Protein (RFVIIIFC) in Previously Treated Paediatric Subjects with Severe Haemophilia A (Kids A-LONG)
    Young, G.
    Mahlangu, J.
    Kulkarni, R.
    Nolan, B.
    Liesner, R.
    Pasi, J.
    Barnes, C.
    Neelakantan, S.
    Gambino, G.
    Cristiano, L. M.
    Pierce, G. F.
    Allen, G.
    HAEMOPHILIA, 2015, 21 : 32 - 32
12345